Skip to main content
. 2015 May 27;89(16):8130–8151. doi: 10.1128/JVI.01221-14

TABLE 5.

Summary of nonhuman primate SIV immunization regimensa

Trial Immunogen Challenge Route Treatment
No. of nonhuman primates with:
Prime Boost 1 Boost 2 Boost 3 Breakthrough Protection Total
M15 SIVmac239 SIVsmE660 Vaginal DNA DNA MVA MVA 5 4 9
M15 SIVmac239 SIVsmE660 Vaginal DNA + GM-CSF DNA + GM-CSF MVA MVA 7 3 10
M2 SIVmac239 SIVsmE660 Vaginal VLP + alum VLP + alum VLP + alum VLP + alum 6 2 8
M2 SIVmac239 SIVsmE660 Vaginal VLP + NP VLP + NP VLP + NP VLP + NP 4 5 9
M2 SIVmac239 SIVsmE660 Vaginal Protein + alum Protein + alum Protein + alum Protein + alum 7 3 10
M2 SIVmac239 SIVsmE660 Vaginal Protein + NP Protein + NP Protein + NP Protein + NP 5 5 10
M11 SIVmac239 SIVsmE660 Rectal DNA DNA MVA MVA 6 2 8
M11 SIVmac239 SIVsmE660 Rectal MVA MVA MVA 6 2 8
M11 SIVmac239 SIVsmE660 Rectal DNA + GM-CSF DNA + GM-CSF MVA MVA 2 5 7
M12 SIVmac239 SIVsmE660 Rectal DNA + CD40L DNA + CD40L MVA MVA 8 4 12
Total 56 35 91
a

DNA, expresses SIVmac239 Gag, PR, Env, Tat, and Rev; MVA, modified vaccinia virus Ankara vector expressing SIVmac239 Gag, Pol, and Env with a truncated gp41; GM-CSF, granulocyte-macrophage colony-stimulating factor adjuvant expressed by a DNA plasmid; VLP, virus-like particles containing SIVmac230 Gag p55 and Env gp160; protein, SIVmac239 Env gp140 plus SIVmac239 Gag p55; NP, poly(lactic-coglycolic acid) nanoparticles with monophosphoryl lipid A and resiquimod (R848); CD40L, CD40 ligand adjuvant expressed by a DNA plasmid.